Because glucagonlike peptide-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors are prescribed for patients with T2D presenting with similar comorbidities (eg, being at high risk of or having already established atherosclerotic cardiovascular and chronic kidney disease), we selected GLP-1 RAs as our comparators to address concerns over confounding by indication.18 We hypothesized that, compared with GLP-1 RAs, SGLT2 inhibitors were associated with lower incidence of DED, probably due to anti-inflammatory effects on ocular diseases. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.